Profile
| Metric | Value |
|---|---|
| Full Name | IDEXX Laboratories, Inc. |
| Ticker | NASDAQ: IDXX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Country | United States |
| IPO | |
| Indexes | |
| Website | idexx.com |
| Employees | 11,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $696.46 | |
| Price, 1D Change | +1.52% | |
| Market Cap | $56B | |
| - | ||
| PE Ratio | 55.21 | |
| Beta | 0.98 | |
| Revenue | $4B | |
| Revenue, 1Y Change | +6.46% | |
| EPS | $10.67 | |
| EPS, 1Y Change | +5.99% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $10.67 | |
| EPS Estimate | $12.90 | |
| EPS Est. Change | +20.97% | |
| Revenue | $3.90B | |
| Revenue Estimate | $4.29B | |
| Revenue Est. Change | +9.95% | |
| Current Price | $696.46 | |
| Price Target | - | $785.00 |
| Price Tgt. Change | - | +12.71% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $9.86 | $10.06 | +2.06% | |
| $10.69 | $10.67 | -0.25% | |
| $12.90 | N/A | +20.97% | |
| $14.42 | N/A | +35.17% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.65B | $3.66B | +0.35% | |
| $3.88B | $3.90B | +0.37% | |
| $4.29B | N/A | +9.95% | |
| $4.66B | N/A | +19.61% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +61.75% | |
| Price, 3Y | +42.46% | |
| Market Cap, 1Y | +58.27% | |
| Market Cap, 3Y | +37.23% | |
| Revenue, 1Y | +6.46% | |
| Revenue, 3Y | +21.22% | |
| EPS, 1Y | +5.99% | |
| EPS, 3Y | +23.96% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $696.46 | |
| SMA 200 | $599.91 | |
| SMA 200 vs Price | -13.86% | |
| SMA 50 | $706.13 | |
| SMA 50 vs Price | +1.39% | |
| Beta | 0.98 | |
| ATR | $17.73 | |
| 14-Day RSI | 47.62 | |
| 10-Day Volatility | 26.72% | |
| 1-Year Volatility | 44.38% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $3.90B | |
| EPS | $10.67 | |
| Gross Profit | $2.37B | |
| Gross Margin | 60.89% | |
| Operating Profit | $1.13B | |
| Operating Margin | 28.92% | |
| Net Income | $887.87M | |
| Net Margin | 22.78% | |
| EBITDA | $1.26B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.62 | |
| Current Ratio | 1.25 | |
| Quick Ratio | 0.90 | |
| - | ||
| F-Score | 8 | |
| Altman Z-Score | 24.33 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 55.21 | |
| PS Ratio | 13.34 | |
| PB Ratio | 35.62 | |
| EV/EBITDA | 39.03 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $1.60B | |
| Cash & Equivalents | $288.27M | |
| Total Assets | $3.29B | |
| Current Assets | $1.34B | |
| Total Liabilities | $1.70B | |
| Current Liabilities | $1.07B | |
| Total Debt | $986.95M | |
| Short Term Debt | $439.33M | |
| Accounts Payable | $114.21M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $3.01B | |
| Operating Expenses | $1.25B | |
| Cost Of Goods Sold | $1.52B | |
| SG&A | $0.00 | |
| D&A | $129.94M | |
| Interest Expense | $0.00 | |
| Income Tax | $221.96M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $929.00M | |
| CFI | -$207.06M | |
| CFF | -$878.07M | |
| Capex | $130.92M | |
| Free Cash Flow | $798.08M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Barclays | ||
| UBS | → | |
| Morgan Stanley | → | |
| JP Morgan | → | |
| BTIG | → | |
| Stifel | → | |
| UBS | ||
| Morgan Stanley | → | |
| Piper Sandler | → | |
| Morgan Stanley | → |
Analyst sentiment
Institutional ownership
Screeners with IDXX
FAQ
What is the ticker symbol for IDEXX Laboratories, Inc.?
The ticker symbol for IDEXX Laboratories, Inc. is NASDAQ:IDXX
Does IDEXX Laboratories, Inc. pay dividends?
No, IDEXX Laboratories, Inc. does not pay dividends
What sector is IDEXX Laboratories, Inc. in?
IDEXX Laboratories, Inc. is in the Healthcare sector
What industry is IDEXX Laboratories, Inc. in?
IDEXX Laboratories, Inc. is in the Diagnostics & Research industry
What country is IDEXX Laboratories, Inc. based in?
IDEXX Laboratories, Inc. is headquartered in United States
When did IDEXX Laboratories, Inc. go public?
IDEXX Laboratories, Inc. initial public offering (IPO) was on June 21, 1991
Is IDEXX Laboratories, Inc. in the S&P 500?
Yes, IDEXX Laboratories, Inc. is included in the S&P 500 index
Is IDEXX Laboratories, Inc. in the NASDAQ 100?
Yes, IDEXX Laboratories, Inc. is included in the NASDAQ 100 index
Is IDEXX Laboratories, Inc. in the Dow Jones?
No, IDEXX Laboratories, Inc. is not included in the Dow Jones index
When was IDEXX Laboratories, Inc. last earnings report?
IDEXX Laboratories, Inc.'s most recent earnings report was on November 3, 2025
When does IDEXX Laboratories, Inc. report earnings?
The next expected earnings date for IDEXX Laboratories, Inc. is February 2, 2026
Data Sources & References
- IDXX Official Website www.idexx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/874716/000087471625000165/0000874716-25-000165-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/874716/000087471625000037/0000874716-25-000037-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- List of NASDAQ 100 Companies www.nasdaq.com/market-activity/quotes/nasdaq-ndx-index
- IDXX Profile on Yahoo Finance finance.yahoo.com/quote/IDXX
- IDXX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/idxx
